NewAmsterdam Pharma (NAMS) Shares Outstanding (2021 - 2026)

NewAmsterdam Pharma has reported Shares Outstanding (Entity) for 6 years, with the latest figure at $57.1 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 4.81% year-over-year to $57.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.1 million (up 4.81% YoY) and the FY2025 annual result came in at $55.6 million, up 25.51% from the prior year.
• Shares Outstanding (Entity) rose to $57.1 million in Q1 2026 per NAMS's latest filing, from $55.6 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $57.1 million in Q1 2026 and troughed at $38.3 million in Q4 2022.
• A 5-year average of $46.1 million and a median of $44.4 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) surged 237.98% in 2022, then grew 0.74% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $38.3 million in 2022, then climbed by 0.74% to $38.6 million in 2023, then increased by 14.84% to $44.3 million in 2024, then grew by 25.51% to $55.6 million in 2025, then advanced by 2.78% to $57.1 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $57.1 million, $55.6 million, and $55.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.